Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is viewed favorably because its pipeline is increasingly anchored by OV329, a next-generation GABA-AT inhibitor that has shown no treatment-related serious adverse events across tested doses and delivered strong biomarker evidence of target engagement, cortical inhibition, and brain penetration, while maintaining dose optionality for upcoming Phase 2 work in treatment-resistant focal onset seizures. The company also has multiple near-term catalysts that can broaden the addressable opportunity, including planned proof-of-concept studies in tuberous sclerosis complex-associated seizures and infantile spasms, alongside a photo paroxysmal response study and regulatory conversations that support an accelerated development path across rare epilepsies. Financially, Ovid reported a 2Q26 net loss of $0.08 per share, held $169.8M in cash, cash equivalents and marketable securities as of June 30, 2026, and is expected to fund operations into 2029, while the separate soticlestat transaction preserves upside through up to $294.5M in potential milestone payments and low- to mid-single digit royalties on net sales.

Ovid Therapeutics is a highly speculative biopharmaceutical company whose investment case depends on unproven early-stage programs rather than durable commercial execution, with its most advanced asset only advancing to Phase 2 and key readouts still ahead in late 2026 and early 2027. The company’s narrative of differentiated, first-in-class or best-in-class mechanisms is offset by substantial clinical risk, including uncertainty around whether OV4071 can reproduce the intended neurotransmitter shift in the ketamine challenge study, whether effects persist beyond the drug’s PK, and whether the planned washout may need to extend beyond 10 days, all of which could weaken confidence in the program’s translational validity. Although OVID projects more than $6B in peak revenue potential across schizophrenia and PDP and management sees incremental value from KCC2 optionality, those figures remain contingent on successful signal generation and proof-of-concept data, leaving the stock vulnerable to disappointment if upcoming studies fail to de-risk the pipeline.